Cargando…

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections

Background and Objectives: The identification of possible biomarkers that can predict treatment response among DME eyes is important for the individualization of treatment plans. We investigated optical coherence tomography (OCT)-based biomarkers that may predict the one-year real-life outcomes amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yen-Chieh, Huang, Yu-Te, Hsu, Alan Y., Meng, Ping-Ping, Lin, Chun-Ju, Lai, Chun-Ting, Hsia, Ning-Yi, Chen, Huan-Sheng, Tien, Peng-Tai, Lin, Jane-Ming, Chen, Wen-Lu, Tsai, Yi-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053215/
https://www.ncbi.nlm.nih.gov/pubmed/36984630
http://dx.doi.org/10.3390/medicina59030629
_version_ 1785015359930105856
author Chang, Yen-Chieh
Huang, Yu-Te
Hsu, Alan Y.
Meng, Ping-Ping
Lin, Chun-Ju
Lai, Chun-Ting
Hsia, Ning-Yi
Chen, Huan-Sheng
Tien, Peng-Tai
Lin, Jane-Ming
Chen, Wen-Lu
Tsai, Yi-Yu
author_facet Chang, Yen-Chieh
Huang, Yu-Te
Hsu, Alan Y.
Meng, Ping-Ping
Lin, Chun-Ju
Lai, Chun-Ting
Hsia, Ning-Yi
Chen, Huan-Sheng
Tien, Peng-Tai
Lin, Jane-Ming
Chen, Wen-Lu
Tsai, Yi-Yu
author_sort Chang, Yen-Chieh
collection PubMed
description Background and Objectives: The identification of possible biomarkers that can predict treatment response among DME eyes is important for the individualization of treatment plans. We investigated optical coherence tomography (OCT)-based biomarkers that may predict the one-year real-life outcomes among diabetic macular edema (DME) eyes following treatment by intravitreal ranibizumab (IVR) injections. Materials and Methods: A total of 65 eyes from 35 treatment-naïve patients with DME treated with ranibizumab injection were recruited. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and OCT scans were retrospectively recorded at baseline before treatment and at 3 months, 6 months, and 12 months after treatment. The OCT scans were evaluated for biomarkers of interest, which included central retinal thickness (CRT), amount and locations of hyperreflective foci (HRF), subretinal fluid (SRF), intraretinal cysts (IRC), large outer nuclear layer cyst (LONLC), ellipsoid zone disruption (EZD), disorganization of retinal inner layers (DRIL), hard exudates (HE), epiretinal membrane (ERM), and vitreomacular interface (VMI). Correlations between these OCT biomarkers and outcome measures (visual and structural) were statistically analyzed. Results: A total of 65 eyes from 35 patients with DME were enrolled. The mean age was 64.2 ± 10.9 years old. Significant improvement in terms of mean BCVA (p < 0.005) and mean CRT was seen at final follow-up compared to baseline. The biomarkers of DRIL, LONLC, and SRF were found to be predictive for at least 50 μm CRT reduction after treatment (with odds ratio of 8.69, 8.5, and 17.58, respectively). The biomarkers of IRC, LONLC, and SRF were predictive for significant improvement in terms of BCVA and CRT after treatment. Finally, the number of HRF was predictive for both BCVA improvement and a CRT reduction of less than 100 μm after treatment. No serious complications were reported during the study. Conclusion: Our study demonstrated the utility of OCT biomarkers as therapeutic predictors of ranibizumab treatment among DME eyes.
format Online
Article
Text
id pubmed-10053215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100532152023-03-30 Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections Chang, Yen-Chieh Huang, Yu-Te Hsu, Alan Y. Meng, Ping-Ping Lin, Chun-Ju Lai, Chun-Ting Hsia, Ning-Yi Chen, Huan-Sheng Tien, Peng-Tai Lin, Jane-Ming Chen, Wen-Lu Tsai, Yi-Yu Medicina (Kaunas) Article Background and Objectives: The identification of possible biomarkers that can predict treatment response among DME eyes is important for the individualization of treatment plans. We investigated optical coherence tomography (OCT)-based biomarkers that may predict the one-year real-life outcomes among diabetic macular edema (DME) eyes following treatment by intravitreal ranibizumab (IVR) injections. Materials and Methods: A total of 65 eyes from 35 treatment-naïve patients with DME treated with ranibizumab injection were recruited. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and OCT scans were retrospectively recorded at baseline before treatment and at 3 months, 6 months, and 12 months after treatment. The OCT scans were evaluated for biomarkers of interest, which included central retinal thickness (CRT), amount and locations of hyperreflective foci (HRF), subretinal fluid (SRF), intraretinal cysts (IRC), large outer nuclear layer cyst (LONLC), ellipsoid zone disruption (EZD), disorganization of retinal inner layers (DRIL), hard exudates (HE), epiretinal membrane (ERM), and vitreomacular interface (VMI). Correlations between these OCT biomarkers and outcome measures (visual and structural) were statistically analyzed. Results: A total of 65 eyes from 35 patients with DME were enrolled. The mean age was 64.2 ± 10.9 years old. Significant improvement in terms of mean BCVA (p < 0.005) and mean CRT was seen at final follow-up compared to baseline. The biomarkers of DRIL, LONLC, and SRF were found to be predictive for at least 50 μm CRT reduction after treatment (with odds ratio of 8.69, 8.5, and 17.58, respectively). The biomarkers of IRC, LONLC, and SRF were predictive for significant improvement in terms of BCVA and CRT after treatment. Finally, the number of HRF was predictive for both BCVA improvement and a CRT reduction of less than 100 μm after treatment. No serious complications were reported during the study. Conclusion: Our study demonstrated the utility of OCT biomarkers as therapeutic predictors of ranibizumab treatment among DME eyes. MDPI 2023-03-21 /pmc/articles/PMC10053215/ /pubmed/36984630 http://dx.doi.org/10.3390/medicina59030629 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chang, Yen-Chieh
Huang, Yu-Te
Hsu, Alan Y.
Meng, Ping-Ping
Lin, Chun-Ju
Lai, Chun-Ting
Hsia, Ning-Yi
Chen, Huan-Sheng
Tien, Peng-Tai
Lin, Jane-Ming
Chen, Wen-Lu
Tsai, Yi-Yu
Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
title Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
title_full Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
title_fullStr Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
title_full_unstemmed Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
title_short Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
title_sort optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after ranibizumab injections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053215/
https://www.ncbi.nlm.nih.gov/pubmed/36984630
http://dx.doi.org/10.3390/medicina59030629
work_keys_str_mv AT changyenchieh opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT huangyute opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT hsualany opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT mengpingping opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT linchunju opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT laichunting opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT hsianingyi opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT chenhuansheng opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT tienpengtai opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT linjaneming opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT chenwenlu opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections
AT tsaiyiyu opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections